In the development of patient-centric injection systems, the consideration points are multifactorial, which would include the drug, primary container, industrial design and branding, as well as end user requirements. These factors could pose a challenge in maintaining the set timelines of the whole combination product development stream. We argue that a flexible design and development model well-integrated through a modular platform device technology can help mitigate project risks and support fast time-to-market.
In this webinar, we discuss a modular platform technology built upon SHL’s Molly® autoinjector. The core Molly technology is designed with integral front and rear subassembly components, resulting in a robust platform that allows for a mix of customizations for industrial design, manufacturing, as well as end user needs. With the rising development of biosimilars not just in the US and Europe – but also in Asia Pacific – a customizable platform to support the distinct and varying requirements of each combination product will be crucial.
Key Learning Objectives
- Identify crucial points in the drug-device development stream where pharma and device developers require tight-knit collaboration
- Acquire learnings from a medical device company with mature processes and infrastructures
- Identify potential risks and how to mitigate them
- Learn about the modular platform technology that is built upon the Molly® autoinjector
